Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Biocryst Pharmaceuticals Inc
English Italiano RARE DISEASES · HAE · EARNINGS · FRANCHISE EXPANSION BioCryst after the transition: why BCRX is no longer just an ORLADEYO story, and why the next leg depends on execution BioCryst is not the same company the market…
FY 2025 marks an inflection point for BioCryst. After years of heavy investment to launch ORLADEYO, the company has finally delivered a clearly profitable year: total revenue reached roughly 875M USD in 2025, versus ~451M USD in 2024, and the P&L flipped from a small operating loss to more than 340M USD of operating profit. The key driver was ORLADEYO net revenue of about 602M USD, up nearly 40% year on year, supported by strong new-patient growth in the U.S. and a better-than-guided performance overall.
(BCRX) Update: FDA Expands ORLADEYO Approval to Younger Children | Merlintrader trading Blog
AGIO, BCRX, MIST: December 2025 PDUFA Deep Dive | Analyst Targets & Timeline
Positive Pediatric Catalyst:
FDA approval on December 12 could represent a doubling of TAM (Total Addressable Market) by adding the completely underserved pediatric segment (zero approved oral therapies).
Report Approfondito BCRX BioCryst Pharmaceuticals in vista del Pdufa di dicembre. E ci metto la faccia :)
BCRX ho sempre avuto un debole per questo titolo, sarà che in passato mi ha datto tante soddisfazioni :) cmq a dicembre ha un espansione della prescrizione per Orl. che aumenterebbe la popolazione a cui si può somministrare il loro farmaco principale. Da grafico proprio ora è nel supporto della trendline, posizione che è più che invitante per un eventuale ingresso in vista del PDFUFA di dicembre. fatevi i conti :)